NRx Pharmaceuticals (NASDAQ:NRXP) Releases Earnings Results, Misses Estimates By $0.35 EPS

NRx Pharmaceuticals (NASDAQ:NRXP) released its earnings results on Friday. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.35), reports.

NRx Pharmaceuticals Trading Down 2.1%

NRXP traded down $0.07 during trading on Friday, reaching $3.27. The stock had a trading volume of 1,124,669 shares, compared to its average volume of 1,198,563. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05. The stock’s 50 day moving average is $3.80 and its two-hundred day moving average is $2.95. The company has a market capitalization of $118.47 million, a price-to-earnings ratio of -3.00 and a beta of 2.18.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. BTIG Research decreased their price target on shares of NRx Pharmaceuticals to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Ascendiant Capital Markets increased their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a report on Monday, April 27th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Monday. D. Boral Capital reissued a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Anson Funds Management LP increased its holdings in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares in the last quarter. Vanguard Group Inc. raised its holdings in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares during the last quarter. Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals in the 4th quarter valued at approximately $994,000. Geode Capital Management LLC raised its stake in shares of NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after purchasing an additional 33,004 shares during the last quarter. Finally, State Street Corp increased its holdings in NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after buying an additional 10,700 shares in the last quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.